Built for advanced diagnostics with complex paths to market.
DMC is selective. We work best where the science is strong, the pathway is non-obvious, and the reimbursement question is genuinely hard.
Proprietary & novel assay developers
Teams taking a differentiated assay from scientific readiness to a defensible reimbursement and commercialization plan.
Molecular & specialty laboratories
High-complexity laboratories in molecular oncology, infectious disease, pathology, toxicology, and women's health.
Genomics & advanced diagnostics companies
Organizations whose economics depend on coverage decisions, evidence, and payer-specific policy.
Laboratories launching new tests
Menu expansion that requires validation, coding, coverage, and billing alignment before the first claim goes out.
Laboratories with complex reimbursement problems
Denial patterns, appeal backlogs, coding integrity gaps, or collections that do not reflect the value of the work performed.
International diagnostics companies
Companies evaluating or executing U.S. market entry and the scientific, reimbursement, and operational requirements it carries.
Biotech & diagnostics companies
Organizations that need commercialization infrastructure without building a full internal commercial function.
Built for diagnostics that do not fit neatly into a standard playbook.
If a generic billing vendor or a generalist consultancy can solve it, you do not need us. If the problem crosses validation, coding, coverage, commercialization, and collections at once, that is exactly where we work.
Senior expertise, directly engaged
The people who scope the engagement are the people who run it.
Selective partnerships
A limited number of engagements, chosen for complexity and fit.
Commercially sharp
Recommendations tied to reimbursement reality, not theoretical strategy.
Current engagements are listed on the clients page; additional work is held in confidence.